ConductScience.org, home

Paper20172016

Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.

Decot V and 6 others. Exp Hematol, 2010. Cited by 56 papers, by iCite.

Cite this record

ConductScience Library. Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. Papers, record 20172016. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20172016

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.
PubMed
Journal
Exp Hematol
PubMed
Year
2010
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
56
iCite
Relative citation ratio, by iCite
1.33
iCite
Revised in PubMed
2010-04-13
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Decot VVéronique
2Voillard LLaure
3Latger-Cannard VVéronique
4Aissi-Rothé LLamia
5Perrier PPascale
6Stoltz JFJean Francois
7Bensoussan DDaniele

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immunotherapy, AdoptiveMajor topic
Interleukin-15Major topic
Interleukin-2Major topic
Interleukin-7Major topic
Killer Cells, NaturalMajor topic
LeukemiaMajor topic
NK Cell Lectin-Like Receptor Subfamily KMajor topic
Receptors, KIR2DL1Major topic
Receptors, KIR2DL2Major topic
Cell Division
Cell Separation
Cells, Cultured
Cytotoxicity, Immunologic
Flow Cytometry
HLA Antigens
Humans
Immunophenotyping

Source PubMed

Download CSV of topics

Cited by36

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 56 citations.

PMIDTitleJournalYearIn PapersSource
41128942Generation of the augmented IL-15-secreting anti-HER2 chimeric antigen receptor (CAR)-NK cells: an encouraging immunotherapeutic tool.Mol Biol Rep2025https://conductscience.org/library/papers/41128942PubMed
40707132Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control.J Immunother Cancer2025https://conductscience.org/library/papers/40707132PubMed
39286242Proliferation capability of natural killer cells upon cytokines stimulation correlated negatively with serum lactate dehydrogenase level in coronary artery disease patients.Front Immunol2024https://conductscience.org/library/papers/39286242PubMed
39133343Computational modeling study of IL-15-NGR peptide fusion protein: a targeted therapeutics for hepatocellular carcinoma.AMB Express2024https://conductscience.org/library/papers/39133343PubMed
37139599Maintenance therapy in acute myeloid leukemia: advances and controversies.Haematologica2023https://conductscience.org/library/papers/37139599PubMed
36060136Bioactivity of Exosomes Derived from Trained Natural Killer Cells versus Non-Trained One: More Functional and Antitumor Activity.Biomed Res Int2022https://conductscience.org/library/papers/36060136PubMed
35639116Natural killer cells and acute myeloid leukemia: promises and challenges.Cancer Immunol Immunother2022https://conductscience.org/library/papers/35639116PubMed
35486482Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy.Blood Adv2022https://conductscience.org/library/papers/35486482PubMed
35286691The Immunogenetics of Alopecia areata.Adv Exp Med Biol2022https://conductscience.org/library/papers/35286691PubMed
34835294The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy.Vaccines (Basel)2021https://conductscience.org/library/papers/34835294PubMed
33946954Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy.Cells2021https://conductscience.org/library/papers/33946954PubMed
33287858Natural killer cell-based immunotherapy for acute myeloid leukemia.J Hematol Oncol2020https://conductscience.org/library/papers/33287858PubMed
32568180Anti-Relapse effects of donor natural killer cells and IL-2 gene modification on allogeneic hematopoietic stem cell transplantation in acute leukemia.Cancer Biomark2020https://conductscience.org/library/papers/32568180PubMed
32480431Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy.J Leukoc Biol2020https://conductscience.org/library/papers/32480431PubMed
30501078Key Role of the CD56lowCD16low Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells.Cancers (Basel)2018https://conductscience.org/library/papers/30501078PubMed
29948616IL-2 And IL-15 Induced NKG2D, CD158a and CD158b Expression on T, NKT- like and NK Cell Lymphocyte Subsets from Regional Lymph Nodes of Melanoma Patients.Pathol Oncol Res2020https://conductscience.org/library/papers/29948616PubMed
29163501Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2.Front Immunol2017https://conductscience.org/library/papers/29163501PubMed
29019081Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15.Immunol Res2017https://conductscience.org/library/papers/29019081PubMed
28622272NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells.J Immunother2017https://conductscience.org/library/papers/28622272PubMed
27356741PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.Oncotarget2016https://conductscience.org/library/papers/27356741PubMed

See all 36 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
IL153600PubTator's text mininghttps://conductscience.org/library/genes/3600NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
IL73574PubTator's text mininghttps://conductscience.org/library/genes/3574NCBI Gene
KIR2DL13802PubTator's text mininghttps://conductscience.org/library/genes/3802NCBI Gene
KIR2DL23803PubTator's text mininghttps://conductscience.org/library/genes/3803NCBI Gene
KLRK122914PubTator's text mininghttps://conductscience.org/library/genes/22914NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20172016

GET https://conductscience.org/api/papers/v1/20172016/cited_by?page=2